Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial

Yajun Shu, Jianfeng He, Rongjuan Pei, Peng He, Zhuhang Huang, Shaomin Chen, Zhiqiang Ou, Jinglong Deng, Peiyu Zeng, Jian Zhou, Yuan‐Qin Min, Fēi Dèng, Hua Peng, Zheng Zhang, Bo Wang, Zhong-Hui Xu, Wuxiang Guan, Zhongyu Hu, Jikai ZhangChinese 2021 · DOI

Abstract

http://www.chictr.org.cn/index.aspx (No. ChiCTR2100045107, http://www.chictr.org.cn/showproj.aspx?proj=124702).
BibTeX
@inproceedings{shu2021immunogenicity,
  author = {Yajun Shu and Jianfeng He and Rongjuan Pei and Peng He and Zhuhang Huang and Shaomin Chen and Zhiqiang Ou and Jinglong Deng and Peiyu Zeng and Jian Zhou and Yuan‐Qin Min and Fēi Dèng and Hua Peng and Zheng Zhang and Bo Wang and Zhong-Hui Xu and Wuxiang Guan and Zhongyu Hu and Jikai Zhang},
  title = {{Immunogenicity and safety of a recombinant fusion protein vaccine (V-01) against coronavirus disease 2019 in healthy adults: a randomized, double-blind, placebo-controlled, phase II trial}},
  booktitle = {Chinese},
  year = {2021},
  doi = {10.1097/cm9.0000000000001702},
}

Loading related content...

Figure